GlassScriptPhysician profile
Firas Aubeid
NPI 1760771968
$7,005.43
in general payments reported to CMS, 2019-2025
32 companies · $935 in 2025
The $935 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $203 · 2021: $194 · 2022: $1,536 · 2023: $2,211 · 2024: $1,926 · 2025: $935.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,223 · Travel and Lodging: $849.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,222.93 |
| Travel and Lodging | $849.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,337.75 | 2021-2023 | Venaseal |
| Astrazeneca Pharmaceuticals LP | $762.95 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $751.75 | 2021-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $468.21 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $426.12 | 2022-2024 | |
| Lilly USA, LLC | $395.63 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $360.26 | 2021-2025 | Pifeltro, Delstrigo, Dificid |
| Glaxosmithkline, LLC. | $335.44 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Gilead Sciences, INC. | $335.42 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $192.14 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $184.20 | 2023-2025 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $181.80 | 2022 | |
| Abbvie INC. | $168.11 | 2023-2025 | Qulipta, Vraylar, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $152.81 | 2021-2023 | Xifaxan |
| Intuitive Surgical, INC. | $132.80 | 2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $107.96 | 2022-2024 | Orencia, Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $95.04 | 2019 | |
| Cequr Corporation | $93.75 | 2024 | Cequr Simplicity |
| Kowa Pharmaceuticals America, INC. | $84.63 | 2025 | Zoryve |
| Janssen Pharmaceuticals, INC | $76.72 | 2022 | |
| Exact Sciences Corporation | $54.61 | 2023-2024 | Cologuard Collection Kit |
| Mylan Specialty L.P. | $48.72 | 2022-2023 | Yupelri |
| Amgen INC. | $44.95 | 2022-2024 | Otezla, Repatha |
| Amarin Pharma, INC. | $44.31 | 2021-2022 | |
| Dexcom, INC. | $32.87 | 2023 | Dexcom G6 Transmitter |
| Edwards Lifesciences Corporation | $31.66 | 2022 | |
| Radius Health, INC. | $27.15 | 2025 | Tymlos |
| Sanofi Pasteur INC. | $19.27 | 2023 | |
| Biohaven Pharmaceuticals, INC. | $15.89 | 2021 | |
| Idorsia Pharmaceuticals US INC | $14.56 | 2022 | |
| Currax Pharmaceuticals LLC | $14.25 | 2025 | Contrave |
| Abbott Laboratories | $13.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Firas Aubeid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.